Navigation Links
Molecular Diagnostics Leader AdvanDx Taps Former Dako Executive Vice President to Lead Global Sales and Marketing Expansion
Date:2/12/2008

WOBURN, Mass., Feb. 12 /PRNewswire/ -- AdvanDx announced it has named Else Beth Trautner, a former Executive Vice President of Dako A/S, as Vice President of Sales and Marketing. Ms. Trautner will aggressively drive the global adoption of AdvanDx's fast, accurate and easy-to-use in vitro molecular diagnostic products that advance the prevention, diagnosis and treatment of infectious pathogens. Ms. Trautner previously managed an organization of more than 575 employees with annual revenues in excess of $300 million at Dako, a global cancer diagnostics company, while successfully restructuring business operations in the Asia-Pacific region that led to record sales. Ms. Trautner also orchestrated the reorganization of 22 sales subsidiaries into 5 geographic regions resulting in 15% sales growth and a 9% increase in profitability during her tenure as Executive Vice President of Global Sales at Dako.

"Ms. Trautner is a seasoned executive with proven industry experience who will drive aggressive growth, market expansion, revenue production and ultimately profitability," said Thais T. Johansen, President and CEO of AdvanDx. "The addition of Ms. Trautner clearly positions AdvanDx to deliver our easy-to-use, life saving molecular diagnostic products worldwide to help treat patients afflicted with serious infections," Mr. Johansen added.

"I am pleased to join AdvanDx's strong business and scientific management team as we make significant inroads into multi-billion dollar markets," said Else Beth Trautner, Vice President of Sales and Marketing at AdvanDx. "I look forward to ramping our success in North America while opening up new markets, seizing revenue-generating sales opportunities and further accelerating the adoption of our products in the global marketplace," said Ms. Trautner.

About AdvanDx

AdvanDx is the world's leading provider of fast, accurate and easy-to-use in vitro molecular diagnostic products that advance the prevention, diagnosis and treatment of infectious pathogens. AdvanDx's products and services enable dramatic improvements in patient care and outcomes while reducing hospital costs.

Every year, 350,000 patients contract bloodstream infections, causing over 90,000 unnecessary deaths and significant costs to the healthcare system. The rapid identification of infecting pathogens is crucial to ensure early and appropriate therapy to save lives and reduce patient length-of-stay. In response, AdvanDx leverages its molecular diagnostic products to detect and identify infectious pathogens and provide therapy-directing results in hours versus days.

AdvanDx's easy-to-use products employ standard lab techniques and equipment to reduce startup, implementation, technician and maintenance time, while providing fast results without sacrificing accuracy. Major medical centers, reference labs, government institutions and community hospitals throughout the United States, Europe and Asia rely on AdvanDx products, supported by a global network of service partners.

For more information visit http://www.AdvanDx.com


'/>"/>
SOURCE AdvanDx
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Acrongenomics on Track to Acquire Molecular Vision
2. Vermillion and Johns Hopkins Sign Collaborative Research and License Agreements to Develop Molecular Diagnostic Tests
3. Acrongenomics Acquires Equity Stake in Molecular Vision
4. Amsterdam Molecular Therapeutics to Appoint Philippe van Holle (Celgene) to Supervisory Board
5. The Dark Report and Siemens Introduce the Worlds First Integrated Molecular Summit
6. The Center for Molecular Medicine Doubles Lab Staff, Expands Lab Space by 100 Percent
7. Peakdale Molecular Announces GBP 1 Million Funding to Support Expansion and Growth
8. Center for Molecular Medicine Selected to Provide DNA Analysis for Childrens Oncology Group Leukemia Study
9. UC Berkeley Expands Molecular Toxicology Curriculum to Include GeneGos Platform
10. Seahorse Bioscience Appoints Former Molecular Devices Executive Dr. Joseph D. Keegan to Board of Directors
11. Center for Molecular Medicine Among First Labs in Nation to Offer Groundbreaking Test to Aid in Treatment of Colorectal Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... June 24, 2016 , ... While the majority of commercial ... Cary 5000 and the 6000i models are higher end machines that use the more ... the spectrophotometer’s light beam from the bottom of the cuvette holder. , FireflySci ...
(Date:6/23/2016)... , June 23, 2016   Boston ... of novel compounds designed to target cancer stemness ... has been granted Orphan Drug Designation from the ... treatment of gastric cancer, including gastroesophageal junction (GEJ) ... inhibitor designed to inhibit cancer stemness pathways by ...
(Date:6/23/2016)... ... June 23, 2016 , ... Charm Sciences, Inc. is pleased ... received AOAC Research Institute approval 061601. , “This is another AOAC-RI approval of ... Salter, Vice President of Regulatory and Industrial Affairs. “The Peel Plate methods perform ...
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... ... today announced the launch of the Supplyframe Design Lab . Located in ... to explore the future of how hardware projects are designed, built and brought ...
Breaking Biology Technology:
(Date:5/3/2016)... , May 3, 2016  Neurotechnology, a ... the MegaMatcher Automated Biometric Identification System (ABIS) ... large-scale multi-biometric projects. MegaMatcher ABIS can process multiple ... using any combination of fingerprint, face or iris ... MegaMatcher SDK and MegaMatcher Accelerator , ...
(Date:4/26/2016)... , April 27, 2016 ... the  "Global Multi-modal Biometrics Market 2016-2020"  report to ... ) , The analysts forecast the ... CAGR of 15.49% during the period 2016-2020.  ... number of sectors such as the healthcare, BFSI, ...
(Date:4/14/2016)... TEL AVIV, Israel , April 14, 2016 /PRNewswire/ ... in Behavioral Authentication and Malware Detection, today announced the ... has already assumed the new role. Goldwerger,s ... for BioCatch, on the heels of the deployment of ... In addition, BioCatch,s behavioral biometric technology, which discerns unique ...
Breaking Biology News(10 mins):